Form 4: Pasithea Therapeutics Corp. Insider Stock Option Grant

Pasithea Therapeutics Corp. reports the grant of stock options to CEO Tiago Marques, with specific vesting conditions and a 10-year expiration.

Summary

• Tiago Marques, CEO and Director of Pasithea Therapeutics Corp., was granted stock options on May 1, 2026.
• The grant includes the right to purchase 1,756,069 shares of common stock at an exercise price of $0.84 per share.
• These options are part of the Issuer's 2023 Stock Incentive Plan.
• Vesting occurs at 33% on the one-year anniversary of the grant date, with the remainder vesting quarterly over the subsequent two years, contingent on continuous service.
• Full vesting is triggered by a Change in Control event.
• Unexercised vested options can be exercised for up to three years post-termination of service, unless terminated for Cause.
• The options expire on April 30, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard executive compensation practice rather than a significant financial event or strategic shift.

Positives

• Grant of stock options to CEO aligns executive compensation with company performance and long-term value creation.
• The vesting schedule encourages executive retention and commitment to the company's success over several years.
• The 'Change in Control' clause provides an incentive for management to maximize shareholder value in potential acquisition scenarios.

Negatives

• The exercise price of $0.84 per share indicates that the stock price needs to significantly increase for these options to be in-the-money.
• The long vesting period and post-termination exercise window mean that the full benefit of these options is deferred.

Risks

• The value of the stock options is directly tied to the future performance of Pasithea Therapeutics Corp.'s stock price, which is subject to market volatility and company-specific risks.
• If the company's stock price does not exceed $0.84 per share, the options will expire worthless.
• Termination of continuous service before vesting, except for a Change in Control, will result in forfeiture of unvested options.

Future Outlook

The future outlook for the stock options is contingent on the company's stock performance exceeding the exercise price of $0.84 and the executive's continued service or a Change in Control event.

Management Comments

• The option award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended.
• Shares underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years, provided that the Reporting Person remains in continuous service to the Issuer through such vesting dates.
• Shares underlying the Option will fully vest upon a Change in Control.
• All vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service, other than a termination for Cause.

Industry Context

StockSavvy.ai notes that the granting of stock options to key executives, such as the CEO, is a common practice in the biotechnology and pharmaceutical sectors to incentivize performance and align interests with shareholders, especially for companies like Pasithea Therapeutics Corp. that are often in growth or development phases.

Stakeholder Impact

• Shareholders: The stock option grant is a form of compensation that dilutes existing shareholders if exercised, but it also aims to align executive interests with increasing shareholder value.
• Employees: The success driven by executive incentives may indirectly benefit employees through company growth and stability.
• Management: Tiago Marques benefits from potential future gains on the stock options, contingent on performance and continued employment.

Next Steps

• Tiago Marques will continue to serve as CEO and Director.
• The stock options will vest according to the schedule outlined, contingent on continuous service or a Change in Control.
• The options can be exercised up to three years after termination of service, provided certain conditions are met.

Key Dates

Keywords

stock options, insider trading, Pasithea Therapeutics Corp., KTTA, CEO compensation, executive stock plan, SEC Form 4, beneficial ownership, vesting schedule, Change in Control